Результаты поиска - Laura M. Spring

Отмена результатов
  1. 1
    The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

    The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer по Laura M. Spring, Yael Bar, Steven J. Isakoff

    Опубликовано 2022
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

    Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations по Laura M. Spring, Mark L. Zangardi, Beverly Moy, Aditya Bardia

    Опубликовано 2017
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    Impact of pass/fail grading on medical students’ well-being and academic outcomes

    Impact of pass/fail grading on medical students’ well-being and academic outcomes по Laura M. Spring, Diana Robillard, Lorrie Gehlbach, Tiffany A. Moore Simas

    Опубликовано 2011
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

    CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions по Laura M. Spring, Seth A. Wander, Mark L. Zangardi, Aditya Bardia

    Опубликовано 2019
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  5. 5
    ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

    ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer по Jamie O. Brett, Laura M. Spring, Aditya Bardia, Seth A. Wander

    Опубликовано 2021
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  6. 6
    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities

    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities по Maxwell R. Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander

    Опубликовано 2021
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  7. 7
    Mechanisms of Resistance to Antibody–Drug Conjugates

    Mechanisms of Resistance to Antibody–Drug Conjugates по Rachel O. Abelman, Bogang Wu, Laura M. Spring, Leif W. Ellisen, Aditya Bardia

    Опубликовано 2023
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  8. 8
    Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

    Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer по Laura M. Spring, Arjun Gupta, Kerry L. Reynolds, Michele A. Gadd, Leif W. Ellisen, Steven J. Isakoff, Beverly Moy, Aditya Bardia

    Опубликовано 2016
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  9. 9
    Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities

    Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities по Laura M. Spring, Erika Nakajima, Jennifer Hutchinson, Elene Viscosi, Gayle C. Blouin, Colin D. Weekes, Hope S. Rugo, Beverly Moy, Aditya Bardia

    Опубликовано 2021
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  10. 10
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer по Rosaria Condorelli, Laura M. Spring, Joyce O’Shaughnessy, Ludovic Lacroix, Caroline Bailleux, Véronique Scott, Jon S. Dubois, Rebecca J. Nagy, Richard B. Lanman, A. John Iafrate, Fabrice André, Aditya Bardia

    Опубликовано 2017
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

    Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies по Yael Bar, Geoffrey Fell, Aylin S. Dedeoglu, Natalie Moffett, Neelima Vidula, Laura M. Spring, Seth A. Wander, Aditya Bardia, Naomi Y. Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff

    Опубликовано 2025
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

    Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis по Laura M. Spring, Geoffrey Fell, Andrea Arfè, Chandni Sharma, Rachel A. Greenup, Kerry L. Reynolds, Barbara L. Smith, Brian M. Alexander, Beverly Moy, Steven J. Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia

    Опубликовано 2020
    Полный текст
    Carta
    Добавить в Избранное
    Сохранить в:
  13. 13
    Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer

    Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer по Laura M. Spring, Rachel A. Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne B. Coopey, Alphonse G. Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle C. Specht, Beverly Moy, Aditya Bardia

    Опубликовано 2017
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

    Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial по Heather L. McArthur, J.H.S. Leal, David B. Page, Aditya Bardia, Laura M. Spring, Christina DiLauro Abaya, Reva Basho, Lindsey Ristow, Hannah Coleman, Stephen L. Shiao, Simon Knott, Mourad Tighiouart, Farnaz Dadmanesh, Sunil Verma, A. E. Giuliano

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

    A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer по Tanya T. Kwan, Aditya Bardia, Laura M. Spring, Anita Giobbie‐Hurder, Mark Kalinich, Taronish D. Dubash, Tilak Sundaresan, Xin Hong, Joseph A. LiCausi, Uyen Ho, Erin J. Silva, Ben S. Wittner, Lecia V. Sequist, Ravi Kapur, David T. Miyamoto, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    <i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

    <i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer по Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis C. Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy

    Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy по Jason I. Griffiths, Jinfeng Chen, Patrick A. Cosgrove, Anne O’Dea, Priyanka Sharma, X. Cynthia, Meghna S. Trivedi, Kevin Kalinsky, Kari B. Wisinski, Ruth O’Regan, Issam Makhoul, Laura M. Spring, Aditya Bardia, Frederick R. Adler, Adam L. Cohen, Jeffrey T. Chang, Qamar J. Khan, Andrea H. Bild

    Опубликовано 2021
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

    Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique по Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura M. Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobágyi, Benjamin H. Kaffenberger, Bernice Y. Kwong, Timothy Pluard, Ruta Rao, Lee S. Schwartzberg, Michael S. Broder

    Опубликовано 2024
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

    Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models по Ioanna Keklikoglou, Chiara Cianciaruso, Esra Güç, Mario Leonardo Squadrito, Laura M. Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B. Ferraro, Caroline Baer, Antonino Cassará, Alan Guichard, M. Luisa Iruela‐Arispe, Claire E. Lewis, Lisa M. Coussens, Aditya Bardia, Rakesh K. Jain, Jeffrey W. Pollard, Michele De Palma

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab по Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia DellʼOrto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: